Innocan Pharma Corporation, a leading entity in the pharmaceutical and biotechnology sectors, has proudly announced the peer-reviewed publication of a narrative review in Cureus journal. The article, titled "Considering Long-Acting Synthetic Cannabidiol for Chronic Pain: A Narrative Review" (DOI: https://doi.org/10.7759/cureus.81577), delves into the significant therapeutic promise of long-acting synthetic cannabidiol (CBD) as a solution for chronic pain. This publication is particularly timely given the urgent global health crisis posed by chronic pain, which affects over 24% of adults in the United States alone, and the pressing need for safer and more effective treatment alternatives.

Co-authored by esteemed pain specialists from renowned institutions such as Johns Hopkins University and NYU School of Medicine, the review underscores that synthetic CBD, when administered through extended-release formulations, could emerge as a well-tolerated, non-opioid analgesic option. This innovative approach holds the potential to substantially reduce the pervasive reliance on highly addictive opioids. Current long-term treatment options for chronic pain are largely inadequate; NSAIDs carry cumulative toxicity risks, while opioids, despite their efficacy, present severe concerns including tolerance, dependency, and a significant risk of overdose. Globally, opioid misuse contributes to more than 100,000 deaths annually.

The U.S. Food and Drug Administration (FDA) has actively emphasized the critical need for novel, non-addictive pain therapies, as outlined in its "Guidance for Industry: Non-Opioid Analgesic Development Programs." Innocan's proprietary LPT-CBD platform is strategically aligned with this regulatory imperative. The LPT-CBD platform represents an innovative injectable liposomal drug product engineered for the sustained release of synthetic CBD. Supported by comprehensive animal studies, LPT-CBD has demonstrated its capacity to maintain steady CBD plasma levels for up to four weeks, provide prolonged pain relief, and exhibit excellent tolerability. These findings position LPT-CBD as a highly promising alternative to existing opioid medications and a crucial tool in combating opioid abuse.

Innocan has initiated crucial regulatory submissions aimed at advancing LPT-CBD into human clinical trials. This progression marks a pivotal moment toward the realization of a first-in-class, non-opioid analgesic therapy meticulously designed to address the intricate challenges of chronic pain management. Dr. Paul J. Christo, Associate Professor and Chief of the Division of Pain Medicine at the Johns Hopkins University School of Medicine and co-author, emphasized, "This publication underscores the urgent need for innovative, non-opioid analgesics that offer long-lasting efficacy. Liposomal synthetic CBD could offer a safe and scalable solution for a variety of painful conditions." Dr. Eugene Vortsman, Clinical Director of Addiction Medicine and Disease Management at Northwell Health and co-author, added, "Given the current addiction crisis, there is an immediate need to replace opioids with safer, effective alternatives. Long-acting synthetic CBD has real potential to shift the paradigm." Iris Bincovich, Chief Executive Officer of Innocan, reiterated the company's commitment, stating, "We are thrilled by this breakthrough publication. Innocan is fully committed to advancing LPT-CBD toward clinical development, with the goal of delivering an innovative and safe non-opioid analgesic solution for chronic pain management."

Beyond its pharmaceutical innovations, Innocan also operates within the wellness sector, developing and marketing a diverse portfolio of high-performance self-care and beauty products through its 60% owned subsidiary, BI Sky Global Ltd. It is important to note that information regarding the Company's plans for human trials of its LPT-CBD platform is forward-looking and subject to various risks and uncertainties, including global economic conditions, governmental and regulatory requirements, and the ability to secure necessary approvals and distribution arrangements. Readers should not place undue reliance on forward-looking information as actual results may differ materially.